Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer.
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) detains a dismal prognosis and has a limited number of prognostic factors. Inflammation has been demonstrated to play a key role both in PDAC initiation and progression and several inflammation-based prognostic scores have been investigated in a wide range of malignancies. We compared the most analyzed inflammation-based prognostic scores in order to establish their potential impact on prediction of the outcome in advanced PDAC patients. METHODS: A total of 234 advanced PDAC patients undergoing first-line chemotherapy in our institute were retrospectively analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using Kaplan-Meier method and survival differences were evaluated using the log-rank test. Level of statistical significance P was set at 0.05. Only those variables that proved to be associated with statistically significant differences in outcome were compared in multivariate analysis using multiple Cox regression, as to identify their independent role and their relative power against each other. RESULTS: In the whole cohort, median overall survival (OS) was 8.7 months (95% CI: 7.8-9.4 months), median progression-free survival (PFS) was 3.8 months (95% CI: 3.1-4.2 months). At univariate analysis high systemic immune-inflammation index (SII) was related to shorter OS [hazard ratio (HR) =2.04, 95% CI: 1.59-4.19, P=0.0001] and PFS (HR =1.52, 95% CI: 1.11-2.20, P=0.01). This was maintained at multivariate analysis both for OS (HR =2.11, 95% CI: 1.29-3.46, P=0.003) and PFS (HR =1.64, 95% CI: 1.14-2.37, P=0.008), whereas other inflammation-based scores lost their independent role. Elevated SII (≥1,200) was associated with low albumin levels (P=0.03) and with elevated lactate dehydrogenase (LDH) (P=0.01). CONCLUSIONS: Elevated SII represents an independent negative prognostic factor above all others for both OS and PFS in advanced PDAC patients treated with first-line chemotherapy, thus confirming a pivotal role of systemic inflammation on PDAC progression and on patient outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SII, SIRI, MHR, NHR, LHR, and PHR are considered cost-effective and simple laboratory parameters indicating systemic inflammation in many diseases (18, 19, 21–23, 26, 27, 30–34).”
From Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have found that the SII has an important role in predicting the prognosis of patients with some physical diseases, such as tumors, cerebral infarction, cardiovascular disease, and acute pancreatitis (18, 20, 21, 36).”
From Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder (2022) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526 · cited 1×
“…patients treated with gemcitabine and nab-paclitaxel, 10 patients presented high SII value ( ≥ 1,200) and these Chemotherapy regimen Folfirinox 46 [20] Gemcitabine plus nab-paclitaxel 52 [22] Gemcitabine 65 [28] Gemcitabine plus cisplatin or oxaliplatin 41 [18] Other (irinotecan, capecitabine,…”
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579 · cited 2×
“On top of that, its incidence is increasing worldwide in both men and women (1).”
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · cited 1×
“Chemotherapy regimens based on fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel showed antitumor activity with an improvement in survival (3,4).”
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 1×
“Chemotherapy regimens based on fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel showed antitumor activity with an improvement in survival (3,4).”
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502 · cited 1×
“The inclusion criteria consisted of: (I) Age >18 years old; (II) Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤3; (III) Histologically or cytologically confirmed diagnosis of PDAC; (IV) Locally advanced not resectable or metastatic PDAC according to the 8th edition of the American Joint Committee…”
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · cited 1×
“More recently, poly (ADP-ribose) polymerases (PARPs) inhibitor olaparib was demonstrated to be effective as maintenance treatment option in germline BRCA1/2 mutated metastatic PDAC patients who had not progressed during first-line platinum-based chemotherapy (5).”
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269 · cited 1×
“Nevertheless, mortality rate is high, and the 5-year survival rate still stands at 9% (6).”
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ducreux, M., Cuhna, A. S., Caramella, C., Hollebecque, A., Burtin, P., Goéré, D., Seufferlein, T., Haustermans, K., Van Laethem, J. L., Conroy, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv295 · Cited by 1,300 · cited 1×
“There is a deep link between PDAC and inflammation: both hereditary and sporadic chronic pancreatitis increase by 10 times the risk of developing PDAC (21,22).”
Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., Templeton, A. J., & Früh, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.024 · Cited by 986
Optimizing the outcomes of pancreatic cancer surgery
Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0112-1 · Cited by 943 · cited 1×
“PDAC is mostly diagnosed at advanced stage and surgery, which is the only potentially curative approach, is feasible only in 15–20% of patients (2).”
Research works printed but not linked: 1
- [22]Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system (4th edition). WHO-IARC, Lyon, 2010.
Cited by
Wei, Y., Wang, T., Li, G., Feng, J., Deng, L., Xu, H., Yin, L., Ma, J., Chen, D., & Chen, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.941728 · Cited by 99
Shui, Y., Li, M., Su, J., Chen, M., Gu, X., & Guo, W. (2021) · Aging · doi:10.18632/aging.203449 · Cited by 57
“The 11 cohort studies were conducted in China (n=4) [12, 14, 15, 17, 18], the Netherlands (n=2) [10], Austria (n=1) [11], Italy (n=1) [16], and the United States of America (USA) (n=1) [13].”
BackgroundJin, M., Yuan, S., Yuan, Y., & Yi, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.735803 · Cited by 54
Mao, L., Li, Z., Wang, Z., Yue, C., Hu, W., & Lü, H. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00785-x · Cited by 53
“For CSS/DFS/PFS, five studies [9, 11, 12, 14, 15] were included in the meta-analysis.”
BackgroundMethodInfluentialWang, S., Wan, Y., & Zhang, W. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s451466 · Cited by 33
Metadata
- Authors
- Bittoni, A., Pecci, F., Mentrasti, G., Crocetti, S., Lupi, A., Lanese, A., Pellei, C., Ciotti, C., Cantini, L., Giampieri, R., Lenci, E., Giglio, E., Bini, F., Copparoni, C., Meletani, T., Baleani, M. G., & Berardi, R.
- Affiliations
- Marche Polytechnic University (IT)
- Corresponding author
- Bittoni, Alessandro
- Pecci, Federica
- ORCID
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2021-02
- Volume
- 9
- Issue
- 3
- Pages
- 251-251
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- PMC
- PMC7940927
- OpenAlex
- W3121703177
- Cited by
- 42
- References
- 52
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 10 · 2023: 13 · 2022: 7 · 2021: 2
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- systemic immune-inflammation index, pancreatic ductal adenocarcinoma, inflammation-based prognostic scores, prognostic factors, overall survival, progression-free survival, first-line chemotherapy, albumin, lactate dehydrogenase, advanced pancreatic cancer, prognostic score comparison, prognostic score validation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. https://app.cochat.ai/papers/10.21037/atm-20-3499
- The paper
- Bittoni, A., Pecci, F., Mentrasti, G., Crocetti, S., Lupi, A., Lanese, A., Pellei, C., Ciotti, C., Cantini, L., Giampieri, R., Lenci, E., Giglio, E., Bini, F., Copparoni, C., Meletani, T., Baleani, M. G., & Berardi, R. (2021). Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. Annals of Translational Medicine. https://doi.org/10.21037/atm-20-3499
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.